Serum erythropoietin during autologous bone marrow transplantation: relationship to measures of erythroid activity.
Marked elevation of serum erythropoietin (sEPO) occurs following high dose chemotherapy for malignant disease. It has been proposed that the subsequent fall in sEPO constitutes a relative erythropoietin (EPO) deficiency, prompting trials of recombinant EPO to reduce red cell transfusion during chemotherapy. We have investigated these phenomena by serial estimations of reticulocytes and sEPO in 11 autologous marrow transplant recipients. sEPO reached two to five times baseline 0 to 5 days after transplant but the inverse relationship between sEPO and haematocrit was maintained. Observed to expected log sEPO (Epo ratio) rose and fell in parallel with sEPO, remaining greater than 1.0 throughout. A progressive fall in reticulocyte count during chemotherapy was followed by an increase during engraftment. The strong inverse relationships between reticulocytes and Epo ratio in the 10 days after initiating chemotherapy support the hypothesis that loss of EPO-receptor bearing erythroid precursors allows a rise in sEPO during chemotherapy. The elevation of Epo ratio levels during engraftment indicates that it is the availability of EPO-sensitive progenitors, rather than the supply of EPO, that limits the rate of resumption of erythropoiesis after high-dose chemotherapy.
Department of Haematology, University of Wales College of Medicine, Cardiff, UK.
S V
SV
Davies
C D
CD
Fegan
R
R
Kendall
Y
Y
Beguin
I
I
Cavill
D000328:Adult; D016026:Bone Marrow Transplantation; D004920:Erythropoiesis; D004921:Erythropoietin / Q000097:blood*; D006400:Hematocrit; D006801:Humans; D007948:Leukemia, Monocytic, Acute / Q000628:therapy; D008875:Middle Aged; D017701:Reticulocyte Count; D012156:Reticulocytes / Q000473:pathology; D014182:Transplantation, Autologous
D004921:Erythropoietin